Alpha-1 antitrypsin (AAT) augmentation therapy in individuals with the PI*MZ genotype: a pro/con debate on a working hypothesis

Overview of attention for article published in BMC Pulmonary Medicine, March 2021

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (82nd percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news: 1 news outlet

twitter: 3 X users

Citations

dimensions_citation: 11 Dimensions

Readers on

mendeley: 37 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 1 news story.

Sanofi to Acquire Inhibrx for Up to $2.2B, with AATD Candidate in Mind

GEN, 23 Jan 2024

Sanofi has agreed to acquire Inhibrx for up to approximately $2.2 billion, in a deal designed to expand the buyer’s pipeline in…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.